Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis

Table 2 Linear regression analysis of S100A9 in 138 rheumatoid arthritis (RA) patients

Variable	β	SE	t	Pvalue	95% Confidence interval
Univariate analysis:
ACPA	0.41	0.21	1.91	0.06	-0.01 to 0.83
Body mass index^a	0.86	0.47	1.84	0.07	-0.07 to 1.78
Diastolic blood pressure	0.02	0.01	1.69	0.09	-0.003 to 0.04
Carriage of PTPN22 Cys1858Thr	0.52	0.24	2.11	0.04	0.03 to 1.00
sRAGE^a	-0.39	0.20	-1.94	0.06	-0.78 to 0.009
S100A8^a	0.20	0.06	3.65	< 0.001	0.09 to 0.31
S100A12^a	0.54	0.10	5.46	< 0.001	0.34 to 0.73
Multivariate analysis:
Body mass index^a	0.86	0.41	2.10	0.04	0.05 to 1.67
S100A8^a	0.11	0.05	2.05	0.04	0.003 to 0.22
S100A12^a	0.46	0.10	4.50	< 0.001	0.26 to 0.67

Variables that were not listed in the simple and multiple linear regression models did not achieve P < 0.1. Adjusted R² of the multiple linear regression model = 0.25.
^aLogarithmic (base e) transformation; S100A9 was logarithmically (base e) transformed.
ACPA, anti-citrullinated peptide antibodies; PTPN22, protein tyrosine phosphatase, non-receptor type 22; sRAGE, soluble receptor for advanced glycation end products.

ISSN: 1478-6362